AMENDMENTS TO THE CLAIMS

Claims 1 to 28 (cancelled)

Claim 29 (currently amended)

A carbohydrate peptide conjugate which induces an antibody response against a carbohydrate tumor antigen, said conjugate being selected from the group consisting of the conjugates of the following formulae (a) to (d)



~~(B1-T1-M)~~



~~(B2-T2-M)~~



~~(B3-T3-M)~~



(B4T4M)



wherein:

- K is a lysyl residue;
- T is A $CD4^+$ cell peptide epitope;
- B is a carbohydrate moiety consisting of a tumor antigen, or a carbohydrate derivative thereof.

~~n:~~

~~B denotes a structurally defined carbohydrate moiety which is a tumor antigen, or a derivative thereof, containing B epitope other than a sialoside, or several identical or different B epitopes;~~

~~T denotes a peptide comprising one $CD4^+$ T epitope or several identical or different T epitopes;~~

~~K denotes a lysine residue;~~

~~n is an integer from 1 to 13;~~

~~m is an integer from 1 to 9; and~~

~~wherein the B and T groups are covalently attached to the poly lysine carrier.~~

Claim 30 (currently amended)

A conjugate of claim 29 wherein ~~the carbohydrate moiety~~ B is galactosyl.

Claim 31 (cancelled)

Claim 32 (currently amended)

A conjugate of claim 29 wherein ~~the carbohydrate moiety~~ B is a galactosyl residue and is substituted with a glycosyl residue.

Claims 33 – 37 (cancelled)

Claim 38 (currently amended)

A conjugate of claim 29 wherein ~~the carbohydrate~~ B is selected from the group consisting of Tn antigen, di-Tn antigen, Tri-Tn antigen, T^* antigen and hexa-Tn antigen.

Claim 39 (previously presented)

A pharmaceutical composition comprising the conjugate of claim 29 and a suitable carrier and adjuvant.

Claim 40 (previously presented)

A vaccine comprising the conjugate of claim 29.

Claim 41 (cancelled)

Claim 42 (previously presented)

An immunogenic composition comprising at least one carbohydrate peptide conjugate of claim 29 wherein said composition is capable of increasing the survival of a tumor bearing human or animal.

Claim 43 (previously presented)

An immunogenic composition comprising at least one carbohydrate conjugate of claim 42 wherein said conjugate comprises different carbohydrate antigens.

Claim 44 (previously presented)

A method of inducing an immune response to at least one member of the group consisting of B-cells and $CD4^+$ T-cells in a human or animal body, wherein the conjugate of claim 29 is administered to said human or animal body.

Claims 45 - 46 (cancelled)

Claim 47 (previously presented)

A method of vaccination of a human or animal body wherein the conjugate of claim 29 is administered to said human or animal body.